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Int roduct ion 
Pituitary adenomas are frequently occurring neo- 
plasms. In unselected pituitaries of adults obtained 
post-mortem a prevalence from 6 up to 23% is 
recorded [I 2]. Using immunocytochemical tech- 
niques, the prevalence of different types of pituitary 
adenomas could be estimated in large series of surgi- 
cally removed pituitary tumours (see Table I) [3 4]. 
While most pituitary adenomas are histologically 
benign, slow-growing tumours, some adenomas 
show a more rapid growth, with extension into the 
surrounding tissues, eventually causing damage to 
the optic nerve(s) and/or other cranial nerves [5]. In 
this manuscript some aspects of the treatment and 
problems which can occur during treatment of each 
of the pituitary adenomas as mentioned in Table I, 
will be described. 
Pro lac t inomas  
Diagnosis 
As mentioned in Table I, ~rolactinomas account for 
approximately 30% of pituitary adenomas. There are 
many reasons for an elevated serum prolactin level, 
such as pregnancy, renal failure, primary hypothy- 
roidism, or the use of medication known to induce 
hyperprolactinaemia (see Table 2). As prolactin is the 
only hormone of which the production is under con- 
stant suppression by dopamine, a sellar abnormality 
in a patient with hyperprolactinaemia may be due 
not only to a prolactinoma, but also to pituitary 
tumours or hypothalamic disorders, which decrease 
dopamine levels (e.g. by compression of the pituitary 
stalk). As serum prolactin levels do correlate well with 
the size of the prolactinoma, a mild degree of hyper- 
prolactinaemia in association with a macroadenoma, 
particularly with extrasellar extension, is usually not 
consistent with a prolactinoma, but with e.g. a non- 
functioning pituitary adenoma [6]. 
Treatment 
The natural history of untreated hyperprolactinaemia 
is not clear [7]. Therefore, in patients with untreated 
microadenomas, clinical symptoms, serum prolactin 
levels, and the appearance of the pituitary gland 
must be carefully monitored. In many patients with 
prolactinomas abnormalities in the secretion of gon- 
adotropin-releasing hormone (GHRH) and gonado- 
tropins lead to a relative or absolute oestrogen de- 
ficiency [8]. This is associated with osteoporosis, so 
despite the relative stability in tumour size, preven- 
tive therapy of hyperprolactinaemia may be necess- 
ary. Although only high oestrogen dosages can cause 
a mild hyperprolactinaemia, the use of oestrogens 
(e.g. as an oral anticonceptive drug) is not advisable. 
Therapy may also be necessary because of reproduc- 
tive dysfunction, infertility, galactorrhoea, as well as 
sexual dysfunction. Treatment of adenomas primarily 
consists of dopaminergic drugs. Neurosurgery is not 
the treatment of first choice because of the very high 
percentage of recurrence [9]. Radiation therapy for 201 
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prolactinomas is also unattractive, because of the 
associated hypopituitarism and the proven efficacy of 
drug therapy [10 11 ]. 
Bromocriptine 
Bromocriptine directly stimulates dopamine recep- 
tors (mainly D 2 receptors) [12]. Bromocriptine is 
capable of improving visual disturbances and re- 
ducing tumour size objectively in patients with large 
prolactinomas within several days or weeks [13]. It 
reduces tumour size by 50% or more in about 50% 
of the patients with a macroprolactinoma and de- 
creases prolactin levels to normal in about 70% of 
the patients [14]. Discontinuation of the therapy may 
be associated with a rapid expansion of tumour size 
and an increase in prolactin levels, so most patients 
require dopaminergic therapy indefinitely [15]. 
However, bromocriptine can be discontinued every 
two years on a trial basis to determine the need for 
continued therapy, as hyperprolactinaemia can re- 
solve spontaneously. 
Side-effects, which are roughly the same for all of 
the dopaminergic drugs, are nausea, orthostatic 
hypotension, headaches, fatigue, nasal congestion, 
abdominal cramps and constipation. Rare side-effects 
are pulmonary fibrosis, vasospasms and psychosis in 
patients with underlying psychiatric disorders [16]. 
The occurrence of side-effects, as well as the need for 
two or three daily doses of bromocriptine, remain 
important problems in the treatment of prolactino- 
ma patients. Therefore, other dopaminergic drugs 
have been developed recently, including meter- 
goline, lisuride, pergolide, mesulergine, terguride, 
dihydroergocristine, dihydroergocriptine, cabergo- 
line and quinagolide. Metergoline, dihydroergo- 
cristine and terguride were less effective than bromo- 
criptine [1 7-19], while lisuride and mesulergine were 
more poorly tolerated than bromocriptine [20 21]. 
Cabergoline, pergolide and quinagolide will be dis- 
cussed in more detail. 
Cabergoline 
A single oral dose of 0.3-0.6 mg cabergoline signifi- 
cantly lowers prolactin levels in hyperprolactinaemia 
for 7-14 days [22]. Given in a dose of 0.4-3.0 mg at 
weekly intervals for 8-9 weeks cabergoline induces 
normalisation of prolactin levels in about two thirds 
of hyperprolactinaemic women [23]. It has been 
shown that most patients are able to tolerate effec- 
tive doses of cabergoline without important side- 
effects [24 25]. These results indicate that cabergo- 
line is a well-tolerated new dopaminergic drug with 
long-lasting activity which represents a potential 
advantage in the chronic treatment of hyperprolacti- 
naemic states. 
Pergolide 
The dopaminergic drug pergolide produced long- 
lasting reductions in prolactin levels after single 
doses of 50 l~g [26]. After 24 hours, the values re- 
mained suppressed at a mean of 29% of the baseline 
value. Liver enzyme disturbances were recorded 
infrequently. Although pergolide is a potent inhibitor 
of prolactin secretion [27], the drug has never found 
an important place in the treatment of hyperprolacti- 
naemic states. In a double-blind study involving a 
total of 157 hyperprolactinaemic patients the efficacy 
and tolerability of bromocriptine and pergolide were 
found to be the same, while the incidence and type 
of side-effects to both dopamine agonists were simi- 
lar [28]. 
Quinagolide 
Quinagolide (an octahydrobenzo[g]quinoline) is a 
non-ergot alkaloid dopaminergic drug, which re- 
cently became available for the therapy of hyperpro- 
lactinaemic states [29]. It is a potent D 2 receptor 
agonist, with only a weak D 1 receptor activity. On a 
weight basis this drug is far more potent than 
bromocriptine in suppressing both normal and 
pathological prolactin secretion [30 31]. These 
promising results were confirmed in several studies, 
all showing the potent inhibitory effect of quina- 
golide on prolactin secretion, as well as on tumour 
size, both in microprolactinoma and in macropro- 
lactinoma patients. Only relatively few patients com- 
plained of side-effects so severe that drug therapy 
bad to be discontinued [32-34]. 
Conclusion 
The treatment of prolactinomas has improved dra- 
matically in the last 20 years. Transsphenoidal hypo- 
physectomy as primary treatment is hardly ever indi- 
cated nowadays. Dopaminergic drugs are effective 
enough to control increased prolactin production 
and turnout growth in the vast majority of patients. 
Considerable tumour shrinkage occurs in most 
patients. An important problem remains that bromo- 
criptine has considerable side-effects, which result in 
a decrease in compliance in part of the patients. The 
development of newer, more specific dopamine D 2 
receptor agonists, e.g. quinagolide, were shown to 
be an improvement in the therapy of macroprolacti- 
nomas in particular, with regard to both the lower 
incidence of side-effects and compliance, because 
this drug can be taken once daily. 
Cushing's disease 
Diagnosis 
When Cushing's syndrome is suspected, two excel- 
lent screening tests are available: the overnight dexa- 
methasone test [35] and the measurement of 24- 
hour urinary excretion of cortisol [36]. After 
hypercortisolism has been confirmed in a patient 
with clinical Cushing's syndrome, the site of hor- 
mone overproduction must be determined. Once 
causes of Cushing's syndrome like medication (cor- 
ticosteroid therapy), alcohol abuse etc. have been 
shown unlikely, one must determine whether 
Cushing's syndrome is caused by Cushing's disease 
(pituitary overproduction of corticotropin), ectopic 
production of corticotropin (or corticotropin- 
releasing hormone) or overproduction of cortisol by 
an adrenal tumour (adenoma or carcinoma). 
To determine whether Cushing's syndrome has a 
pituitary or non-pituitary cause can be very difficult. 
A continuous dexamethasone infusion (1 mg/h) for 
7 h seems to be a superior diagnostic tool for this dif- 
ferential diagnostic problem [37]. The corticotropin- 
releasing hormone stimulation test is also a reliable 
test with high sensitivity and specificity [38]. Mag- 
netic resonance imaging seems to be a better way of 
localizing pituitary corticotropin-secreting microade- 
nomas than computer-tomographic scanning [39 
40]. A major advance in the diagnosis of Cushing's 
disease has been sampling of corticotropin in both 
inferior petrosal sinuses and measuring the central- 
to-peripheral corticotropin ratio [41 42]. 
Bilateral catheterization of the inferior petrosal 
sinus before surgery is recommended in all patients 
for whom dynamic testing is consistent with pituitary 
tumour but imaging studies are inconclusive. 
Treatment 
The therapy of choice for patients with Cushing's dis- 
ease is selective transsphenoidal adenomectomy. The 
reported rates of surgical cure are as high as 90% in 
patients with microadenomas. If sellar exploration 
does not reveal a tumour, hemihypophysectomy can 
be performed with the use of the lateralization data 
obtained from preoperative bilateral measurement of 
corticotropin in the inferior petrosal sinuses. Primary 
conventional radiotherapy leads to biochemical and 
clinical improvement in only 15 to 25% of adult 
patients [43] while neurological complications occur 
relatively frequently. 
Drug therapy of patients with Cushing's disease 
may be used to control severe hypercortisolism be- 
fore curative surgery, as an adjunctive treatment in 
patients who have received radiotherapy, or to treat 
patients who are not surgical candidates. Agents that 
inhibit the production of cortisol are also useful in 
the treatment of patients with ectopic corticotropin 
syndrome. A number of pharmacological agents 
block the adrenal system. 
Metyrapone 
Metyrapone is an 11~3-hydroxylase inhibitor, which 
decreases cortisol secretion, while the production of 
11-deoxycortisol and dehydroepiandrosterone is 
increased [44]. It has been used in the treatment of 
Cushing's disease. In doses up to 2 g daily, bio- 
chemical and clinical remission can be achieved [45]. 
Nausea, vomiting and dizziness can occur. The drug 
can also cause hirsutism due to the overproduction 
of adrenal androgens, as well as hypertension, hypo- 
kalaemic alkalosis and oedema, due to the accumu- 
lation of 11 -deoxycortisol. 
Aminoglutethimide 
Although originally developed as an anticonvulsant 
drug, aminoglutethimide is now also used as a drug 
against hypercortisolism. It inhibits primarily the 
cholesterol side-chain cleavage enzyme which is 
involved in the synthesis of corticosteroids as well as 
the aromatase enzyme which converts androgens to 
oestrogens. It causes gastrointestinal side-effects, 
somnolence and a transient rash in therapeutical 
doses of 1-2 g daily. Steroid withdrawal symptoms 
are inevitable and replacement therapy by cortico- 
steroids is required [46]. However, in the long term, 
the use of this agent is limited by its lack of thera- 
peutic efficacy and by side-effects, including gastro- 
intestinal symptoms and (often severe) somnolence. 
Ketoconazole 
Ketoconazole, an antimycotic agent, is an imidazole 
derivative which inhibits mitochondrial cytochrome 
P-450 enzymes. The major activity appears to be the 
inhibition of 17-20 desmolase. A moderate blockade 
of 17-hydroxylase may be present, while there is a 
marked inhibition of 21- and/or 11-hydroxylase. It 
thus inhibits the conversion of androgens to oestro- 
gens, of progesterone to androstenedione and tes- 
tosterone, and of 11-deoxycorticosterone to cortico- 
sterone [47]. Started in doses of 800-1,200 mg daily 
and with maintenance doses of 600-800 mg daily, 
ketoconazole is relatively well tolerated, although 
liver enzyme disturbances can be a problem. It has 
been proven to be effective in the treatment of 
hypercortisolism in most types of Cushing's syn- 
drome [48-51]. One potential benefit of ketocona- 
zole is that while the cortisol levels decrease, there is 
not necessarily a proportionate increase in corticotro- 
pin levels. It is felt that ketoconazole may have a 
pituitary effect on decreasing corticotropin secretion 
[52]. Ketoconazole should be considered the initial 
drug therapy of choice in the majority of patients 
with Cushing's syndrome who require adjunctive 
treatment. However, the effects of long-term use 
have not been established. 203 
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Mifepristone 
The properties of mifepristone (RU 38486, RU 486), 
a steroid with powerful blocking activity at the pro- 
gesterone and the glucocorticoid receptor, have 
been studied both in vitro and in vivo [53]. In normal 
humans, mifepristone blocks glucocorticoid negative 
feedback at the hypothalamic-pituitary level, in- 
ducing a compensatory increase in plasma cortico- 
tropin and cortisol levels [54]. After one single-dose 
oral gift of 400 mg, mifepristone induces a response 
that lasts at least 34 h. When ketoconazole is unable 
to lower cortisol production and if the clinical con- 
dition requires a rapid, more or less acute total 
blockade of cortisol receptors (i.e. acute psychosis), 
the use of mifepristone should be considered [55]. 
Unfortunately, the drug cannot be titrated very well 
because there are no objective biological parameters 
to measure its effects. The blocking effects on the 
cortisol receptor in man can be antagonized by very 
high doses of dexamethasone [56]. 
Conclusion 
The treatment of Cushing's syndrome depends en- 
tirely on its cause. The diagnosis of Cushing's syn- 
drome due to ectopic corticotropin or corticotropin- 
releasing hormone production seems to be improved 
by the introduction of new procedures, like petrosal 
sinus catheterization and the use of magnetic reson- 
ance imaging. Also, several new drugs have become 
available. Both drugs blocking adrenal cortisol pro- 
duction (e.g. ketoconazole) and cortisol receptor 
blocking agents like mifepristone seem to have a 
place in the treatment of Cushing's syndrome. These 
drugs are better capable of controlling the clinical 
effects of hypercortisolism in Cushing's syndrome 
than the older ones. They still have considerable 
side-effects and, in the case of mifepristone treat- 
ment, monitoring the degree of cortisol receptor 
blockade is difficult, if not impossible. 
Non-functioning tumours 
Diagnosis 
The majority of so-called non-functioning pituitary 
adenomas are slowly growing macroadenomas with 
extrasellar extension. As such tumours do not have a 
characteristic linical syndrome of excessive hormone 
production, they can grow to a considerable size 
before they are detected. Symptoms like headache, 
insidious visual loss and hypopituitarism are the most 
frequent occurring symptoms. These tumours pre- 
sent themselves at a relatively high age (50-80 years) 
[57]. When they produce gonadotropins, they are 
called gonadotropinomas. The pituitary glycoprotein 
hormones are composed of a common c~ subunit as 
well as J3 subunits specific to each hormone. The el- 
evation of serum cz or 13 subunit concentrations 
therefore seems to be an independent tumour 
marker and independent of alterations in the levels 
of other pituitary hormones. In some cases a para- 
doxical rise in one or several of these hormones to 
thyrotropin-releasing hormone can be helpful in 
establishing the diagnosis [58]. 
Treatment 
As most of the clinically non-functioning pituitary 
adenomas present themselves with visual field 
defects, neurosurgical decompression is often necess- 
ary. In principle the transsphenoidal approach is 
the primary therapy, although recent publications 
of experienced groups do report a considerable 
perioperative risk [59 60]. 
Pharmacotherapeutic possibilities with these 
tumours are somatostatin analogues, like octreotide, 
and dopaminergic drugs [61 62]. Possibly in the 
future gonadotropin-releasing hormone antagonists 
will also be of potential therapeutic use [63]. 
Octreotide 
Experience with octreotide is limited and consist of 
only some case reports. In most cases no reduction 
in tumour size was seen, but, remarkably, a fast 
improvement in visual capabilities was described in 
some patients. Whether this is the result of just a very 
small reduction in tumour size or a direct effect of 
octreotide on the retina or optic nerve is presently 
unknown. 
Quinagolide 
In a recent report in a small group of 5 patients with 
clinically non-functioning pituitary adenomas the use 
of the dopaminergic drug quinagoline was investi- 
gated. Both an improvement in visual disturbances 
and a decrease in tumour size and a significant 
decrease in gonadotropin and/or subunit levels was 
observed [64]. Larger studies are necessary, though, 
to confirm these results. 
Conclusion 
The treatment of non-functioning tumours of the 
pituitary gland is primarily a surgical one, largely 
because of the size of these tumours, often leading 
to panhypopituitarism and visual disturbances. If 
these complications are not present, one can be 
more conservative. Hopefully in the future more 
results will become available proving beneficial 
results of treatment with dopaminergic drugs and/or 
somatostatin analogues. 
Acromegaly 
Diagnosis 
Although human somatic growth is regulated pri- 
marily by growth hormone, most of its growth-pro- 
moting effects are mediated by insulin-like growth 
factor I (IGF-I), which is largely synthesized in the 
liver, but is also produced in the kidney, muscle, 
pituitary gland, chondrocytes and the gastrointes- 
tinal tract [65]. As a negative feedback mechanism, 
IGF-I suppresses growth hormone-mRNA synthesis in 
the pituitary gland [66]. Although most of the 
growth hormone's growth-promoting actions are 
mediated by IGF-I, animal models suggest that the 
hormone and IGF-I act independently and synergisti- 
cally in skeletal and organ growth [67]. 
Because of the apparent manifestation of the dis- 
ease, acromegaly is usually diagnosed clinically. In 
most studies a positive correlation between tumour 
size and basal growth hormone levels has been 
found [68 69]. Up to levels of about 50-80 ilg/I, 
growth-hormone concentrations correlate well with 
serum IGF-I levels, suggesting that growth-hormone 
levels of about 60 pg/I stimulate IGF-I production 
maximally [70 71]. Several authors have reported a 
correlation between age and tumour volume, while 
others could not find such a relationship [72]. 
The two most sensitive tests for biochemical confir- 
mation of the hypersecretion of growth hormone are 
measurements of plasma IGF-I and an oral glucose 
tolerance test, which is more time-consuming but 
still is the golden standard. Random determinations 
of growth-hormone levels are rarely useful in the 
diagnosis of acromegaly. For screening purposes, 
IGF-I levels are specific in the diagnosis of acro- 
megaly, as they correlate well with mean 24-hour 
plasma growth-hormone concentrations. 
Treatment 
As acromegaly is associated with an increase in the 
expected mortality rate [73], it has to be treated 
either by surgery, drug therapy or radiotherapy (or 
any combination of these). Considering the fact that 
50% of the patients with growth-hormone levels 
< 5 ~g/I after surgery, do still have elevated IGF-I 
levels [74], a real cure of acromegaly by surgery 
might be rare. So other means of therapy or combi- 
nations of therapy are often necessary. When in- 
creased growth-hormone production still persists 
after surgery, or when there are contra-indications 
for surgery, external conventional radiotherapy can 
be used as treatment. This method is capable of 
reducing growth-hormone levels in a majority of the 
patients to < 5 i~g/I, although normal growth- 
hormone levels are only reached after several years 
[75]. Acquired hypopituitarism as a (late) compli- 
cation of radiation therapy occurs in more than 50% 
of the patients [76]. 
Bromocriptine 
As relatively large doses of bromocriptine are necess- 
ary to induce clinically beneficial effects [77] this 
drug is not so often used as a primary therapy for 
acromegaly, but more often as an adjuvant herapy 
[78]. In less than 20% of the patients, bromocriptine 
is capable of reducing growth-hormone l vels to less 
than 5 F~g/I, while only in 8% of the patients normal- 
ization of IGF-I levels is achieved. 
Octreotide was found to be more effective in 
lowering growth-hormone l vels than bromocriptine 
[79]. In a recent study by Chiodini et al. quinagolide 
was as potent in reducing growth-hormone l vels as 
bromocriptine. No patients insensitive to bromocrip- 
tine were sensitive to quinagolide [80]. 
Octreotide 
Since the introduction of octreotide, therapy of acro- 
megaly has become much more successful [81]. 
Octreotide (50 t-[g as a single dose, subcutaneously), 
suppresses growth-hormone secretion within 1 h. 
Maximal suppression of growth-hormone levels is 
reached after 3 h. The response may be sustained up 
to 12 h [82]. The drug reduces tumour volume in 
50% of the patients [83]. It reduces growth-hor- 
mone secretion in 90% of the acromegalic patients, 
normalizes IGF-I levels in 60% and, because the 
course of serum growth-hormone levels after a single 
dose of octreotide correlates well with the serum 
growth-hormone levels reached during long-term 
treatment with octreotide, this substance has be- 
come the drug of first choice in the medical treat- 
ment of acromegaly [84]. It is usually well tolerated, 
although it inhibits gallbladder contractility, causing 
the development of gallstones [85]. It decreases 
headaches in most patients and long-term therapy 
with octreotide reduced serum IGF-I levels in several 
groups of acromegalics by 37 to 81%. 
Good selection of patients by age, sex and tumour 
size is necessary. Not all patients need a trans- 
sphenoidal operation, which has its own morbidity 
and appears to be seldom radical in large invasive 
adenomas. Especially in older (male) acromegalic 
patients one can probably primarily choose for 
octreotide therapy and omit transsphenoidal surgery. 
Also, one can predict the ultimate efficacy of octreo~ 
tide therapy in controlling hormonal hypersecretion 
by monitoring the degree of decrease of growth-hor- 
mone secretion after a single dose of octreotide. 
Other somatostatin analogues, such as the long- 
acting BIM 23014, are tested for their usefulness in 
acromegaly now and some reports describe a poten- 
tially beneficial role [86]. 
Conclusion 
The treatment of acromegaly has considerably 
improved after the introduction of octreotide. Con- 
trol of hormonal hypersecretion can also be achieved 
in part of the patients by octreotide therapy. If 
tumour size is a problem on its own, octreotide is 
not the treatment of choice, because the extent of 
tumour shrinkage is in most instances disappointing. 
In this case surgery (often in combination with radio- 
therapy) is mandatory. After surgery octreotide ther- 
apy should be considered in order to control clinical 
symptomatology related to residual acromegaly. 205 
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